Elan's $1B Royalty Buy Beefs Up Hostile Takeover Defense
Elan Corp. PLC said Monday that it will pay drugmaker Theravance Inc. $1 billion for the rights to future royalty payments, proving to shareholders it can pull off big deals and...To view the full article, register now.
Already a subscriber? Click here to view full article